Disclosure: The research for CALGB 70903 was supported in part by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chair) and to the CALGB Statistical Center (Daniel J. Sargent, PhD, CA33601) as well as National Institutes of Health Support Grant P30-CA-008748. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The authors have no financial relationships to disclose.
Original Research Article
Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903
Article first published online: 30 OCT 2012
Wiley Periodicals, Inc
Volume 13, Issue 11, pages 1417–1424, November 2012
How to Cite
Atkinson, T. M., Halabi, S., Bennett, A. V., Rogak, L., Sit, L., Li, Y., Kaplan, E., Basch, E. and Cancer and Leukemia Group B (2012), Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. Pain Medicine, 13: 1417–1424. doi: 10.1111/j.1526-4637.2012.01498.x
- Issue published online: 14 NOV 2012
- Article first published online: 30 OCT 2012
- National Cancer Institute. Grant Number: CA31946
- CALGB Statistical Center. Grant Number: CA33601
- National Institutes of Health Support. Grant Number: P30-CA-008748
- Cancer Pain;
- Quality of Life
The Brief Pain Inventory (BPI) was designed to yield separate scores for pain intensity and interference. It has been proposed that the pain interference factor can be further broken down into unique factors of affective (e.g., mood) and activity (e.g., work) interference. The purpose of this analysis was to confirm this affective/activity interference dichotomy.
Patients and Methods
A retrospective confirmatory factor analysis was completed for a sample of 184 individuals diagnosed with castrate-resistant prostate cancer (age 40–86, mean = 65.46, 77% White non-Hispanic) who had been administered the BPI as part of Cancer and Leukemia Group B trial 9480. A one-factor model was compared against two-factor and three-factor models that were developed based on the design of the instrument.
Root mean squared error of approximation (0.075), comparative fit index (0.971), and change in chi-square, given the corresponding change in degrees of freedom (13.33, P < 0.05) values for the three-factor model (i.e., pain intensity, activity interference, and affective interference), were statistically superior in comparison with the one- and two-factor models. This three-factor structure was found to be invariant across age, mean prostate-specific antigen, and hemoglobin levels.
These results confirm that the BPI can be used to quantify the degree to which pain separately interferes with affective and activity aspects of a patient's everyday life. These findings will provide clinical trialists, pharmaceutical sponsors, and regulators with confidence in the flexibility of the BPI as they consider the use of this instrument to assist with understanding the patient experience as it relates to treatment.